Notable quotes by Jimmy CarterNotable quotes by Jimmy Carter
Iowa U.S. Sen. Joni Ernst noncommittal on Trump's nomination to U.S. Defense DepartmentDonald Trump is returning to the world stage. So is his trolling
Bitcoin has surpassed the $100,000 mark as the post-election rally continues. What's next?
AP News Summary at 5:15 p.m. ESTNone
ANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024 . In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon . To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025 , before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagement until March 31, 2026 . TransMedics also updated its 2024 financial outlook. Dr. Waleed Hassanein , Mr. Gerardo Hernandez and Mr. Stephen Gordon will attend the upcoming Piper Sandler Conference on December 3, 2024 , the TransMedics Investor & Analyst Day on December 10, 2024 , as well as the J.P. Morgan Healthcare Conference in January 2025 . Mr. Hernandez is an accomplished finance leader with over 25 years of experience across the healthcare and consumer packaged goods (CPG) sectors. He most recently served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals, a biopharmaceutical company focused on RNAi therapeutics. In this role, Mr. Hernandez led a global team as the company scaled rapidly. Prior to his role at Alnylam, Mr. Hernandez spent nearly a decade at Shire, where he rose through the organization, eventually leading corporate FP&A. During his tenure, Shire was acquired by Takeda in a $62 billion transaction, after which he was instrumental in the integration effort. Mr. Hernandez began his career at Unilever where he held several finance roles of increasing responsibility before joining Shire in 2010. Mr. Hernandez holds a Bachelor of Science degree in Finance from the University of Wisconsin , La Crosse and an MBA in Strategy and Economics from Fundação Getulio Vargas , Sao Paulo, Brazil . "Stephen has been an exceptional partner to me as a member of the TransMedics leadership team for nearly a decade. During his tenure we transitioned the Company from a clinical stage organization to a high growth, publicly traded commercial business," said Waleed Hassanein , M.D., President and Chief Executive Officer. "On behalf of the entire management team and the Board, I want to thank Stephen for his countless contributions to our business that will have lasting benefits for the Company. I am grateful for Stephen's dedication and efforts to advance our corporate strategy while delivering considerable shareholder value, and I look forward to his continued partnership to affect a smooth transition as we start our next chapter at TransMedics." "I am delighted to welcome Gerardo to the TransMedics leadership team as our new Chief Financial Officer," added Dr. Hassanein. "His proven record over two decades of leadership across FP&A functions within high-growth, complex global organizations makes him an ideal addition to our team. I am looking forward to partnering with Gerardo as we continue to deliver significant long-term corporate growth and shareholder value." "I am thrilled to join TransMedics as Chief Financial Officer," said Mr. Hernandez. "I look forward to working with the entire leadership team to expand access to the Company's unparalleled products and services in the organ transplant field while enhancing operational efficiency and delivering lasting value to both our shareholders and the patients we serve." Dr. Hassanein concluded, "As we enter the final weeks of the fourth quarter, we are also updating our financial outlook for the full year 2024. Our updated guidance reflects our continued expectation for considerable year-over-year revenue growth. We look forward to providing additional context at our upcoming Investor & Analyst Day." 2024 Financial Outlook TransMedics now expects revenue for the full year 2024 to be in the range of $428 million to $432 million, which represents 77% to 79% growth compared to the Company's prior year revenue. Piper Sandler 36th Annual Healthcare Conference Members of the TransMedics management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024 , at 4:00 p.m. Eastern Time . A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . The Company's standard investor presentation is also available through this link. TransMedics Investor & Analyst Day Details TransMedics will discuss the transition and updated financial outlook, as well as the Company's growth strategy, clinical pipeline, and operations, in greater detail at its Investor & Analyst Day in New York City on Tuesday, December 10, 2024 , at 10:00 a.m. Eastern Time . A live and archived webcast of presentations and Q&A sessions will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . Please note management will only take questions from the live audience during the question-and-answer session following formal presentations. About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Forward-Looking Statements This press release contains forward-looking statements with respect to, among other things, a leadership transition and our full-year guidance. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: our ability to maintain profitability on a sustained basis; our ability to attract, train and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the Organ Care System or OCS; our ability to expand access to the OCS through our National OCS Program or NOP; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States , the European Union, and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration or FDA, or other competent authorities, follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP and reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration or FAA or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Investor Contact: Brian Johnston Laine Morgan 332-895-3222 Investors@transmedics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/transmedics-appoints-gerardo-hernandez-as-chief-financial-officer-and-provides-updated-2024-financial-outlook-302320060.html SOURCE TransMedics Group, Inc.Ottawa customers turning to couriers to get holiday packages shipped as Canada Post strike continuesTransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook
Lam Research Corporation Comments on Newly Announced Export Regulations
Comedian David Walliams has opened up about his gender and sexuality, describing himself as “non binary”. The former Britain’s Got Talent judge made the candid admission during an interview on the Uncomfortable Conversations podcast , hosted by Australian presenter Josh Szeps. During a dialogue about gender politics and identity, the Little Britain star admitted that if were a young person today, he’d probably identify as “non-binary”. When asked how he’d describe himself if he were a teenager now, David answered: “I don’t know. I mean, I think in a way I’d probably say I’m non-binary, I think. Probably. I don’t know exactly.” David Walliams has opened up about his gender and sexuality on Aussie podcast Uncomfortable Conversations. Walliams said that if he was a young person today, he’d probably identify as “non-binary”. He also said that as a drama student he was inclined to be more experimental. He said: “I sort of think, where would I be positioning myself maybe, if I was now 19 or 20. Because I went to Bristol University and did a drama degree. And I think that course is where you’re probably... if there’s a group of people who are going to be most interested in that sort of area, most drawn to that area, it’s probably going to be drama students.” The 53-year-old described how he enjoyed going out to gay clubs during his student days with his girlfriend at the time in tow. “I mean, it’s interesting. So I had this girlfriend at the end of university and we used to go out — I used to go out — we used to go to like gay clubs and dance for like six hours and I’d be wearing like a skirt or stuff like that.” Walliams said that as a drama student in university, he was inclined to be more experimental. Picture: Tristan Fewings/Getty Images Then podcast host Josh asked the comedian and author a direct question about his sexuality. He said: “And what about your sexuality?” You always lean into Britain’s most famous bi-curious comedian. Was that a real reflection of your adolescence did you fool around with guys?” The Boy in the Dress author then responded by saying, “Yeah I’d say so, but again it seems odd because these things were a big deal to talk about.” But then the TV star and author underscored that sexuality doesn’t need to be set in stone as he described the differences between himself and his former comedy Little Britain co-star, Matt Lucas. “Sometimes I think my life would be a lot easier if I was just gay. Because I’m really drawn to gay things. I really like gay culture. It’s interesting because Matt Lucas is gay. And he’s like into football and he’s into musicals as well, actually... But yeah I’d say I’m probably sort of camper than him. It’s hard, I don’t know.” With Little Britain co-star Matt Lucas. In light of the conversations and awareness of gender identity in the last decade, David also suggested that his debut novel, The Boy in the Dress , was ahead of its time. He said: “ The Boy in the Dress 15 years ago, which was sort of seen as a bit more daring then, and it’s always something - I’ve always sort of felt like celebrating difference on, so I’ve always thought it’s exciting.” The writer and comedian has an 11-year-old son, Alfred from his relationship with model Lara Stone. The pair married in a lavish ceremony in London’s Claridge’s hotel in 2010 and were together for five years before filing for divorce in 2015. Since making his name in TV comedy through his popular sketch shows, Little Britain and as a judge on Britain’s Got Talent , David has become one of the most successful children’s author’s of all time, selling 50 million copies of his books worldwide. This article originally appeared in The Sun and was reproduced with permission More Coverage Hit sitcom returns for ‘last ever’ episode Christine Estera Megan Fox wears see-through dress, lingerie Kelsey Stewart – Page Six Originally published as David Walliams says he’s ‘probably non-binary’ and reveals ‘everyone assumes’ he’s gay Celebrity Life Don't miss out on the headlines from Celebrity Life. Followed categories will be added to My News. More related stories Entertainment Megan Fox wears see-through dress, lingerie Megan Fox has always loved a totally sheer fabric – and that certainly hasn’t changed now she’s expecting baby number four. Read more Celebrity Life Items found next to Liam’s body revealed Haunting new details of Liam Payne’s final hour suggest the One Direction star was trying to escape from his hotel room before falling to his death. Read more
Two U of A researchers named fellows of inventors' academyThe U.S. government makes a major travel advisory change for China
PyroGenesis Canada Inc. (PYR.V) ( CVE:PYR – Get Free Report ) shares shot up 11% during mid-day trading on Friday . The company traded as high as C$3.99 and last traded at C$3.85. 335,425 shares were traded during trading, a decline of 1% from the average session volume of 337,985 shares. The stock had previously closed at C$3.47. PyroGenesis Canada Inc. (PYR.V) Price Performance The company has a debt-to-equity ratio of 165.50, a quick ratio of 0.32 and a current ratio of 0.32. The company has a market capitalization of C$606.96 million and a price-to-earnings ratio of -154.00. The company has a 50-day moving average price of C$3.85 and a 200-day moving average price of C$3.85. About PyroGenesis Canada Inc. (PYR.V) ( Get Free Report ) PyroGenesis Canada Inc designs, develops, manufactures, and commercializes advanced plasma processes and systems in Canada and internationally. It offers DROSRITE, a sustainable process for enhancing metal recovery from dross targeting primarily metallurgical industry; plasma atomized metal powders; PUREVAP, a process to produce high purity metallurgical grade silicon and solar grade silicon from quartz; plasma fired steam generator, which directly generates steam suitable for steam-assisted gravity drainage (SAGD) for the oil and gas industry; and custom reactors and furnaces for use in advanced materials, metallurgical, environmental, and chemical fields. Read More Receive News & Ratings for PyroGenesis Canada Inc. (PYR.V) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PyroGenesis Canada Inc. (PYR.V) and related companies with MarketBeat.com's FREE daily email newsletter .Matt Gaetz Bows Out: A Political Shift Amid Controversy
BUFFALO — The year started with a bang. In January, Gov. Kathy Hochul named UB the home of Empire AI, a new $400 million supercomputing center that will provide UB and partners with breathtakingly powerful resources to harness artificial intelligence for the betterment of society. An avalanche of advancements – all pointing towards UB’s leadership in AI, in New York State and nationwide – followed the governor’s announcement. With interest in AI surging globally, these advancements showcase and build upon UB’s impressive half-century of expertise in AI research and education. They also hint at a brighter future, where AI’s uncanny abilities merge with human ingenuity to tackle society’s greatest challenges. “Traditionally, colleges and universities are at the epicenter of life-changing research and ideas,” said Venu Govindaraju, vice president for research and economic development. “The University at Buffalo is pushing the boundaries of artificial intelligence and data science in fields that are critical to the state’s and nation’s future.” As 2024 comes to a close, here’s a look back at what has been a year of AI at UB. January UB researchers have been laying the groundwork for today’s boom in artificial intelligence for decades. This includes pioneering work creating the world’s first autonomous handwriting recognition system, which the U.S. Postal Service and Royal Mail adopted to save billions of dollars. Those innovations explain, in part, why Gov. Kathy Hochul chose UB to be the home of Empire AI, a consortium of public and private universities, and foundations, that will harness AI for the public good while driving economic development. “We want to make sure New York State is the capital of AI development ... but I need a home for this supercomputer that’ll power the innovation all over our state. And I’m proud to announce that the home will be right here at [UB],” Hochul said Jan. 26 at the Center for the Arts. Earlier in the month, during her State of the State address in Albany, the governor spotlighted UB student Holliday Sims for her work using AI to improve the child welfare system. February UB was chosen to join the federal government’s first-ever consortium dedicated to ensuring that AI systems are safe and trustworthy. Announced Feb. 8, the U.S. AI Safety Institute Consortium (AISIC) includes government agencies and top research universities, as well as Microsoft, Apple, Google, OpenAI and other tech companies. AISIC will create standards for AI usage that protect Americans’ privacy; advance equity and civil rights; and promote innovation and competition. Weeks later, UB was among 28 new members to join AI Alliance, an international coalition led by IBM and Meta that is dedicated to promoting open, safe and responsible AI. March On a beautiful spring day, engineering professor Chase Murray and students took to the skies at UB’s Structure for Outdoor Autonomy Research, one of the largest outdoor drone-testing labs among the nation’s colleges and universities. Murray uses AI and other technologies to optimize how autonomous vehicles work together – research that has implications in logistics, search-and-rescue, surveillance and more. Elsewhere, researchers in UB’s Institute for Artificial Intelligence and Data Science kept tabs on their AI system that aims to improve indoor farming and address food insecurity. And another research group began using AI to make algae fuel production more cost-effective. The projects illustrate UB’s commitment to sustainability and social justice. April April brought Senate Majority Leader Charles Schumer and Sethuraman Panchanathan, director of the National Science Foundation, to campus. The occasion? “Today, we’re here to celebrate something truly amazing: the opening of the new, $20 million, federally funded National AI Institute for Exceptional Education, and it’s going to be housed right here at UB,” said Schumer. Funded by the NSF and Department of Education, the institute will create AI systems that ensure children with speech and language disorders receive timely, effective assistance. The work, which addresses the nationwide shortage of speech-language pathologists, will help ensure that millions of children do not fall behind in their academic and socio-emotional development. May On May 31, UB hosted thought leaders from IBM, M&T Bank, Moog and other institutions for its ongoing chat series on AI and society. “Don’t be an AI user, be an AI value creator,” Dario Gil, IBM senior vice president and director of research, told attendees at the Center of Excellence in Bioinformatics and Life Sciences. The event included presentations from UB researchers using AI to make advancements in medicine, medical devices, climate change, materials science, pharmaceutical science and other fields. June An electricity grid that uses AI to identify and fix problems before they cause widespread power outages? It could become reality sooner than you think due to research published June 4 and co-led by Souma Chowdhury, who studies how to apply AI to complex systems. He is among more than 200 researchers at UB using AI to address societal challenges. Also in June, more than 300 scholars from the Association for the Advancement of Artificial Intelligence, one of the world’s most recognized scientific organizations dedicated to advancing AI research, gathered at UB for a multiday conference. The scholars represented more than a dozen fields – including machine learning, psychology, political science, the humanities and more. July On July 17, SUNY Chancellor John B. King Jr. and state lawmakers visited UB for a roundtable discussion on AI. The attendees learned about UB researchers using AI to identify “forever chemicals,” as well as spinoff companies working on technology to improve treatment for strokes and aneurysms. “We are pioneering AI discoveries that will drive progress in research and economic development, demonstrating UB’s commitment to leveraging technology for societal benefit,” Govindaraju said. August The start of the new semester brought record enrollment to UB’s Master of Science program focusing on AI. Launched in 2020 with five students, the number swelled to 73 students this fall, with an additional 50 expected next semester. The program’s growth “shows that we’re providing students with in-demand skills that they can use for the betterment of society,” said Kemper E. Lewis, dean of the School of Engineering and Applied Sciences. Graduates have taken jobs at Amazon Web Services, NVIDIA, Visa and other companies. September UB was awarded $10 million from the U.S. Department of Education to establish the Center for Early Literacy and Responsible AI. The center will create AI tools to ensure culturally and linguistically diverse learners in grades K-2, including those in Western New York, receive transformative early literacy instruction. “We believe that, with the right support, all students — regardless of their backgrounds — can succeed in literacy,” says project leader X. Christine Wang, a professor of learning and instruction in the Graduate School of Education. Later in the month, Rep. Tim Kennedy announced UB would receive $475,000 to equip its wind tunnel with equipment that allows it to leverage the power of AI, among other technologies. UB uses the facility to study and improve the nation’s response to hurricanes, wildfires and other extreme weather. October On Oct. 11, roughly nine months after it was announced, Empire AI went live. Gov. Kathy Hochul flipped the switch on a stack of powerful new computer servers at Center of Excellence in Bioinformatics and Life Sciences. The servers represent a fraction of the eventual power of Empire AI, which will be located at a new building on North Campus. On the same day, UB President Satish K. Tripathi delivered his annual State of the University address. “While today, only the private sector has the computing power needed to seriously advance AI research, Empire AI will put New York State at the epicenter of artificial intelligence innovation. This game-changing initiative will enable us to tap the full power of AI to solve complex issues facing our state, nation and world.” November From fake celebrity endorsements to manipulated videos of politicians, the 2024 election was rife with misleading information. Debunking much of this content was the DeepFake-o-Meter, a publicly available tool used by journalists, law enforcement and others. The tool was created by UB computer scientist Siwei Lyu and students. With AI being added to medical devices, the Food and Drug Administration wants to ensure these products meet public health standards. The agency called upon experts, including UB’s Peter Elkin, for insight at a public meeting. Elkin, professor and chair of the Department of Bioinformatics, said the FDA should allow these devices to learn and therefore improve. “AI-enabled devices are no longer just tools; now they are partners in care,” he said. Back on campus, UB hosted the latest in a series of “AI at UB” forums on Nov. 21. Organizers updated faculty and staff on how UB is implementing AI in its classrooms and labs. Presenters also discussed how AI can be a tool to foster collaboration and enhance learning outcomes. December In early December, UB officials detailed plans to create a new academic department focused on AI and its impact on society. The department aligns with the mission of UB and SUNY, both of which are committed to responsibly harnessing the power of AI for social good. Around the same time, UB computer scientist Nalini Ratha published a series of research papers focused on machine learning and encrypted data. One of the papers suggests a new technique for safeguarding personal medical data as it travels from third-party cloud service providers back to patients and their doctors. The work points to a future where medical diagnostics are quicker and more accurate, and patient medical records remain confidential.